Market Preview, June 18, 2026: RVNL Bags Rs 968-Crore Bridge Order, Lupin Launches US Generic, HFCL Wins BharatNet Deal, FILA Trims DOMS Stake, and Bosch Home Comfort OFS Set to Keep Markets Busy on Thursday

Mumbai, June 18: Thursday promises to be a busy day for investors as they track Rail Vikas Nigam stock after it bagged big order from East Coast Railway. Pharma major Lupin stocks will be tracked for its generic medicine launch in the US market. Bosch Home Comfort OFS will also be under scanner. Here’s what you should track. 

Rail Vikas Nigam (RVNL) — Secures Rs 967.93-Crore EPC Order from East Coast Railway 

Rail Vikas Nigam Ltd (RVNL) has secured a Letter of Acceptance from East Coast Railway for the construction of bridges under the EPC model, as part of the third and fourth railway line expansion between Nergundi-Barang and Khurda Road-Vizianagaram on the Bhadrak-Vizianagaram route. The order is valued at Rs 967.92 crore and covers construction of four major Open Web Steel Girder bridges over the Birupa, Mahanadi, Kathjori and Kuakhai rivers. The project, spanning roughly 385 km in total, is aimed at strengthening rail connectivity and increasing line capacity on one of the country’s key freight and passenger corridors, with execution expected over a three-year period. The win adds to RVNL’s already substantial order book and reinforces its positioning as a key player in India’s railway infrastructure expansion.  

Lupin (LUPIN) Launches Generic Hypertension Drug in the US with 180-Day Exclusivity 

Global pharmaceutical company Lupin (LUPIN) has announced the launch of Azilsartan Medoxomil Tablets in 40 mg and 80 mg strengths in the United States after receiving approval from the US FDA for its Abbreviated New Drug Application (ANDA). The product is bioequivalent to Edarbi of Azurity Pharmaceuticals and is indicated for the treatment of hypertension in adults to lower blood pressure. Lupin said it is the exclusive first-to-file applicant for the product and is eligible for 180 days of generic drug exclusivity in the US market, with Azilsartan Medoxomil Tablets having estimated annual US sales of $53.5 million according to IQVIA data. The launch adds to Lupin’s cardiovascular portfolio in the US and comes on the back of a strong Q4, with consolidated profit after tax rising sharply to Rs 1,468.70 crore, up 87.72% year-on-year. The stock will be tracked for incremental revenue contribution from the exclusivity window. mexc + 2 

HFCL (HFCL) Wins Rs 2,666-Crore BharatNet Phase-III Order from RVNL 

HFCL has received a contract worth Rs 2,666.09 crore from Rail Vikas Nigam for the BharatNet Phase-III project in Uttar Pradesh. The scope includes supply of telecom equipment and accessories, creation of an optical fiber cable telecom network, and maintenance of the project for 10 years. The order is among the larger telecom infrastructure wins for HFCL this year and strengthens its position in India’s rural broadband rollout, a segment that has seen renewed government push as part of the broader digital connectivity agenda. The stock will be watched for execution timelines and margin commentary on the decade-long maintenance component. 

DOMS Industries (DOMS) — Promoter FILA Offloads 7% Stake for Rs 935 Crore 

Italian stationery giant FILA (Fabbrica Italiana Lapis ed Affini SpA), the foreign promoter of DOMS Industries, offloaded a 7% equity stake comprising 42.48 lakh shares for Rs 934.7 crore. Of the total shares sold, FILA offloaded 23.4 lakh shares at Rs 2,200.55 per share and 19.08 lakh shares at Rs 2,200.07 per share. The stake sale, executed via block deals, will be closely watched for its impact on the stock’s free float and any signal it sends about promoter confidence, even though such offloads by financial sponsors are often driven by portfolio rebalancing rather than company-specific concerns. 

Bosch Home Comfort (BOSCH-HCIL) Promoter to Divest Up to 7.97% Stake via OFS 

Promoter Bosch Global Software Technologies plans to divest up to a 7.97% stake, equivalent to 21.7 lakh shares, in Bosch Home Comfort through an offer-for-sale scheduled for June 18-19. The OFS window will give institutional and retail investors an opportunity to participate in the stake sale, and the stock is likely to see heightened volatility and volume through the two-day sale period as the market digests the floor price and overall demand for the offering. 

Source:

• bseindia.com
• nseindia.com
• Company press releases
• psuwatch.com
• business-standard.com
• prnewswire.com